Research
Hormonal
Behavioral interventions, orlistat, and metformin all reduce diabetes incidence in patients with prediabetes or elevated risk, with behavioral interventions cutting incidence by about 50% or more over 2-3 years.
If you have prediabetes, behavioral weight loss programs can cut your risk of developing type 2 diabetes by half or more over 2-3 years. Orlistat and metformin also reduce risk, but behavioral interventions are the most robustly supported for this outcome.
GoodSupportsMEDIUM confidence
All intervention types reduced diabetes incidence, particularly in patients with elevated risk... Behaviorally based interventions... cut diabetes incidence by about 50% or more over 2 to 3 years... Metformin and orlistat reduced diabetes incidence.
Why this rating
Based on multiple trials, though orlistat data reliability is questioned.
Source
Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force
Erin S. LeBlanc et al. · Annals of Internal Medicine · 2011
DOI 10.7326/0003-4819-155-7-201110040-00006
Meta-analysis · 58 studiesCited 403×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Behaviorally based weight-loss interventions result in statistically significant weight loss (average 3.0 kg or 6.6 lb greater than control) at 12 to 18 months, with greater intervention intensity (12-26 sessions) yielding greater loss (4-7 kg).Good
- Orlistat combined with behavioral intervention results in greater weight loss (average 3.0 kg or 6.6 lb more) than placebo plus behavioral intervention at 12 months, though with higher rates of gastrointestinal adverse effects leading to withdrawal.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →